Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels

G. Bertelli, P. Pronzato, D. Amoroso, M. P. Cusimano, P. F. Conte, G. Montagna, S. Bertolini, R. Rosso

Research output: Contribution to journalArticle

Abstract

The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p

Original languageEnglish
Pages (from-to)307-310
Number of pages4
JournalBreast Cancer Research and Treatment
Volume12
Issue number3
DOIs
Publication statusPublished - Dec 1988

Keywords

  • adjuvant endocrine therapy
  • antithrombin III
  • plasma lipids
  • tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels'. Together they form a unique fingerprint.

  • Cite this